(Circulation. 1995;92:14-19.)
© 1995 American Heart Association, Inc.
Articles |
Late Outcome After Coronary Artery Bypass Graft Surgery in Patients <40 Years Old
From the Departments of Cardiology (J.K.F., D.S.S., W.M.S.), Clinical Physiology (R.M.L.W., H.D.N., M.V.), and Cardiothoracic Surgery (A.R.K.), Green Lane Hospital, Auckland, New Zealand.
 |
Abstract |
|---|
 Top Abstract IntroductionMethods Results Discussion References |
|---|
Background Randomized trials confirm the long-term efficacy of coronary artery bypass graft surgery (CABG), although there are no randomized data in patients <40 years old. Because these patients have been reported to have an early recurrence of symptoms, the long-term postoperative outcome was examined.
Methods and Results The long-term outcome of patients
(n=221)
<40 years old undergoing CABG at Green Lane Hospital, New Zealand,
from 1970 to 1992 was determined. The 30-day mortality rate was 1.8%
for initial and 9.5% for redo CABG. The median times to angina or
myocardial infarction (recurrent ischemic event), further
intervention, and death were 6.0, 9.6, and 14.2 years, respectively.
Factors associated with increased late mortality on
univariate analysis included
end-systolic volume (ESV) 
80 mL (P=.004;
10-year mortality 19% versus 39% ESV 80 mL), no internal mammary
conduit (P=.01), no lipid-modifying therapy
(P=.005), and no postoperative aspirin use
(P=.0002); the latter was also associated with increased
recurrent ischemic events (P=.04) or increased
reintervention (P=.02). On stepwise logistic regression
analysis, factors associated with increased late mortality were
increasing ESV (P=.004), no internal mammary artery conduit
(P=.009), diabetes (P=.04), and no
postoperative
aspirin (P=.02); the latter was also associated with
increased recurrent ischemic events (P=.02).
Hypercholesterolemia (6.5 mmol/L) was
present in 65% of patients at presentation and 45% at
follow-up.
Conclusions To attempt to prevent recurrent ischemia or late death, patients <40 years old who require CABG should receive internal mammary conduits, aspirin, lipid-modifying therapy, therapy to inhibit ventricular dilatation, and strict diabetes management.
Key Words: bypass • lipids • aspirin • diabetes mellitus • cardiac volume
|
Introduction |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
The surgical management of patients with severe coronary artery disease improves long-term survival, which has recently been confirmed in an overview of randomized trials of CABG.1 However, subgroup analysis according to clinical risk, which includes age, suggested that some low-risk patients may not have a significant mortality benefit from surgery. For example, when the subgroup of patients <47 years old was compared with older age groups in the European trial, there was no mortality benefit for surgery at 10 years.2 The reasons for this age-dependent difference in the relative mortality benefit of CABG are not immediately apparent but may reflect both a lower mortality in medically treated younger patients2 and surgical crossover. Also, a higher prevalence of factors associated with early graft occlusion, such as an elevated total and/or low HDL cholesterol and persistent cigarette smoking,3 4 5 has been reported in younger patients.6 7 8 9 10 The possible role of other potential factors that may be associated with an unfavorable long-term outcome, such as diabetes and hypertension, is equivocal.6 7 8 9 10 Since several studies have shown that in the year after CABG there is considerable inattention to correction of adverse risk factors by patients and/or physicians,11 12 13 suboptimal treatment of these may impact the long-term outcome after coronary surgery in younger patients. Antiplatelet therapy confers a 30% benefit in terms of graft patency at 1 year,14 15 but whether this is translated into a beneficial effect on long-term outcome in young patients after CABG is unknown.
In this study, we examined the entire surgical experience at Green Lane Hospital from 1970 to 1992 in patients who were <40 years old at the time of CABG to determine the attention paid to risk factors such as dyslipidemia, smoking status, and the use of antiplatelet therapy in this group of post-CABG patients. The impact of variables known to influence long-term outcome, such as ventricular function and the use of mammary conduits, was also assessed.
|
Methods |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
The long-term outcome was evaluated in all patients who underwent a first CABG operation at age <40 years at Green Lane Hospital from 1970 through 1992. Evaluation was performed in 1993. Patients with reoperation before age 40 years were included only once for analysis. Follow-up information was obtained by clinical and case note review as well as detailed questionnaires to physicians and patients similar to those previously described.16
The preoperative variables included sex, race, smoking history
(current or stopped 
1 year, stopped 1 to 10 years, stopped >10
years, or never smoked), serum lipids (and whether action had been
taken to rectify any abnormalities), family history of premature
coronary artery disease in first-degree relatives (women
60 and men 50 years old, respectively), hypertension (on therapy
and/or blood pressure 150/95 mm Hg), diabetes (on insulin or fasting
glucose 6.5 mmol/L), class of angina (Canadian
Cardiovascular Society), previous Q-wave myocardial
infarction, left ventricular end-diastolic
pressure, left ventricular ESV, presence of left main
coronary stenosis of 50% (reduction in lumen
diameter), and myocardial score.17
The operative data included the number of distal grafts, the use of IMA
conduits, bypass and cross-clamp times, and
perioperative development of new Q waves and/or
elevation of aspartate aminotransferase (100
U/mL).18
The long-term follow-up data included vital status, recurrence of angina or further infarction, the necessity for further cardiac intervention (CABG, angioplasty, or cardiac transplantation), follow-up lipid levels, use of lipid-modifying therapy, aspirin therapy, and postoperative smoking history (defined as admitting smoking regularly for at least 1 month in the postoperative period).
Actuarial analyses (Kaplan-Meier) were applied to assess unfavorable surgical outcomes, ie, recurrence of angina/myocardial infarction, further intervention, and death. Statistically significant differences between data sets were determined by two-tailed Student's t tests and univariate analysis. Multivariate analysis using stepwise logistic regression and Cox proportional-hazards models examined the factors that were associated with an adverse outcome.
|
Results |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Patient Population
There were 239 CABG operations performed on patients <40 years old at Green Lane Hospital during the years 1970 through 1992, and patients were followed up for 8.3±5.1 years. Eleven patients had two or more operations at age <40 years, and 7 patients had CABG only as a secondary procedure at the time of aortic root replacement for dissection or aortic valve replacement. Therefore, the data presented here are from the 221 patients who had initial CABG as the primary procedure at age <40 years.
Preoperative Patient and Catheterization
Data
The main preoperative patient characteristics are summarized in
Table 1
. The majority of patients (148 of 218, 68%)
underwent CABG for severe angina (Canadian
Cardiovascular Society class III or higher). There was
a high incidence of hypercholesterolemia (104
of 159 [65%] with total cholesterol 6.5 mmol/L [250
mg/dL]), with a mean cholesterol level of 7.21±1.65
mmol/L; current or recent smoking (61%); and a family history of
premature coronary heart disease (39%); whereas the incidences
of hypertension and diabetes were 17% and 5%, respectively.
|
The
preoperative angiographic data are summarized in Table 2.
Twenty-six patients (12%) had 50% left main
coronary stenosis. The mean preoperative ejection
fraction on left ventriculography was 57.9±13.1%, and ESV was
79.3±47.4 mL. Sixty-four percent of patients (128/201) had a
myocardial score of 10, ie, the approximate equivalent of
triple-vessel disease17 on coronary
arteriography, and 12% had 50% left main stenosis.
|
Operative Data
The 221 patients received a total of 518
saphenous vein graft
distal anastomoses. Forty-four patients had single IMA conduits (no
patients had bilateral mammary conduits). There were 4 deaths (1.8%)
within 30 days of surgery. By a relatively conservative assessment of
either new Q waves and/or a peak aspartate aminotransferase 100
IU/mL, 21 patients (9.5%) had perioperative
infarcts.
Long-term Follow-up
Ten patients were lost to follow-up after
the
perioperative period. The median times until death,
intervention, or a further ischemic event (either recurrent
angina or myocardial infarction) were 170, 136, and 72 months,
respectively (Fig 1). Survival at 10 years after surgery
was 74%. There were 58 further interventions (28%). Forty-two
patients (20%) had further CABG, with a 30-day mortality at
reoperation of 9.5%. In addition, 12 patients (5.6%) had
postoperative coronary angioplasty, and 5 patients (2.4%)
underwent cardiac transplantation. If the cohort was equally divided
into pre–January 1, 1981 (n=107) and post–January 1, 1981
cohorts
(n=104), there were no differences in the incidences of postoperative
recurrent ischemia (P=.67) or late mortality
(P=.98) (Fig 2). After 1984, coronary
angioplasty and the use of mammary conduits, aspirin, and
lipid-modifying therapy became more prevalent. The cohort was
therefore also divided into pre–January 1, 1985 (n=165; 11 CABGs
per
year) and post–January 1, 1985 (n=46; 5.8 CABGs per year); there
were
no differences in either late mortality (P=1.00) or
recurrent ischemic events (P=.43).
|
|
On univariate
analysis, several factors were
associated with an increased actuarial mortality during long-term
follow-up (Fig 3). These included an increased ESV
80 mL (P=.004; the 10-year mortality was 39% versus 19%
for ESV <80 mL), the lack of use of an IMA conduit (P=.01),
the lack of postoperative aspirin therapy (P=.0002), and the
lack of lipid-modifying therapy (P=.005). Of these, only
the postoperative use of aspirin was associated with a significant
reduction in further ischemic events (P=.04) or
further intervention (P=.02).
|
Several potentially
adverse factors were included in a
multivariate model to predict determinants of
long-term mortality (Table 3). Stepwise logistic
regression analysis showed that a smaller ESV (continuous
variable, P=.004), the use of IMA conduits
(P=.009), postoperative aspirin (P=.02), and
the
absence of diabetes (P=.04) were all associated with a
better long-term mortality outcome. Multivariate
analysis using the Cox proportional-hazards model was also
performed. Increasing ESV (P=.01), the lack of aspirin
postoperatively (P=.01), diabetes (P=.05), and
the lack of lipid-modifying therapy (P=.03) were
significant adverse factors (the lack of an IMA conduit,
P=.11).
|
While postoperative smoking (28% of patients)
showed a trend toward
being an adverse factor affecting increased late mortality,
hypertension did not (Table 3
). There were 83 patients (45%)
who did
not receive any postoperative aspirin. Of the 101 patients (55%) who
received aspirin postoperatively, only 49 were treated preoperatively
and 8 within 1 month of surgery, so the beneficial effect of aspirin
may well be underestimated.
Lipid data were not always recorded,
particularly in the early
years of this cohort. However, on univariate
analysis, those patients without baseline lipid data had the
same late mortality (P=.34). The use of postoperative
lipid-modifying therapy rather than cholesterol was
included in the logistic regression model, but this factor did not
reach statistical significance (P=.11). Inclusion of
baseline cholesterol, which reduced the total number of
observations, did not affect the significance of the other factors. At
review, 45% of patients (59/132) remained
hypercholesterolemic (>6.5 mmol/L) (Table 4). There were no
statistical differences in the other
baseline characteristics of those patients who did and did not have
follow-up lipid data, nor was there any difference between those
who had complete lipid analysis versus those who had
analyses of only total cholesterol and
triglycerides.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
This study has examined the actuarial outcome of patients <40 years old who underwent CABG at Green Lane Hospital between 1970 and 1992. During most of this era, the usual bypass conduit was the saphenous vein graft. IMA grafts were not routinely used at Green Lane Hospital before the mid-1980s, which coincided with an approximate halving of the annual surgical rate for younger patients due to the use of angioplasty as a revascularization procedure.
The 10-year postoperative mortality of 26% reported here was the same
as that reported from Johns Hopkins19 for similar patients
in the same era. Patients in the Johns Hopkins series had slightly more
left main stenosis (15% versus 12%) and slightly better
ventricular function than those reported here, with 89%
having an ejection fraction 45% compared with 87% with an ejection
fraction >40%. The number of grafts per patient was also similar (2.7
versus 2.5). However, the risk profiles of patients were somewhat
different, with more patients having hypertension (35% versus 17%)
and diabetes (17% versus 5%) and currently smoking (74% versus 61%)
in the Johns Hopkins series;
hypercholesterolemia (250 mg/dL, or 6.5
mmol/L) was similar to that reported here (64% versus 65%). In
contrast to the Johns Hopkins experience, we found no increase in the
percentage of women or diabetics in our post–January 1, 1981
cohort.
In a recent report of a smaller series from France, 86 patients <40
years old with less extensive disease requiring 1.9 grafts per patient
had IMA grafts to the left anterior descending artery in all cases and
an excellent long-term outcome, with only 7% mortality at 10
years,20 but these patients had fewer distal anastomoses
compared with our series. In the European Coronary Surgery
Study,2 patients <47 old years had a 10-year mortality of
20% following initial surgical or medical treatment, although these
patients had generally less severe disease than those in our series. It
is not clear whether this represents a better outcome with
medical treatment or, alternatively, whether it may represent
expeditious crossover to surgery. The Cleveland Clinic
series6 of patients <36 years old also had slightly lower
10-year mortality, although patients in that series received more IMA
conduits and had less marked dyslipoproteinemia, and fewer patients had
left main stem stenosis (2.8%).
Although a medical cohort is not included in this series, there is an
age-matched control group from the New Zealand population. Compared
with age-matched control subjects in previous series from our
institution, which reported long-term post-CABG outcome in all
patients (mean age, 54 years) undergoing surgery in 1976 and
197716 and those 70 years old (mean age, 71 years)
undergoing surgery in 1981 through 1985,21 patients in the
present series did not have as good a relative late outcome. This
may be due in part to an increased incidence of occult ischemic
heart disease in older individuals in the general population. A recent
report from Oregon of their entire surgical experience also showed that
the youngest patients (<45 years old) had a poorer long-term
mortality outcome than those in some older age
groups.22
Although there have been improvements in myocardial protection over the past two decades, it is unlikely that perioperative technique was a major contributor to this relatively unsatisfactory late mortality outcome, since the operative mortality rate (death at <30 days) was 1.8%. There is clearly a significant risk at reoperation, with 9.5% 30-day mortality. When total bypass time and clamp time were included in the multivariate analysis, these variables were not significant predictors of an adverse late outcome.
As previously reported from this institution,23 24
we have
shown that increased mortality is positively associated with poorer
ventricular function but, in particular, increasing ESV.
The 10-year postoperative mortality more than doubled (39% versus
19%) in those patients with a preoperative ESV of 80 mL. A recent
report from our institution examining increased preoperative
ESVs24 found that ESV >130 mL was most highly associated
with increased mortality. This index of ventricular
function was the strongest single predictor of a poor
long-term mortality outcome on multivariate
analysis.
The data show that in this group of young patients after CABG, there is
a high incidence of dyslipidemia that has not always been
optimally treated, with 45% of patients having cholesterol
6.5 mmol/L (250 mg/dL) at the time of review. Others have reported
similar results in unselected patients after
CABG.11 12 13
HMG-CoA reductase inhibitors can achieve a 30% to 40%
reduction in total and LDL cholesterol25 26
and also increase HDL cholesterol. Lipid-modifying
therapy can cause coronary artery disease regression, so that
patients with coronary artery disease, especially those with
saphenous vein grafts,3 25 should be treated
aggressively.
More than 60% of the patients in this series met eligibility criteria
for enrollment in the Scandinavian Simvastatin Survival
Study,27 which showed 30% and 42% reductions in total
and coronary heart disease deaths, respectively.27
One would anticipate that the use of HMG-CoA reductase
inhibitors in patients similar to those described here,
especially for patients with cholesterol 5.5 mmol/L, may
achieve similar benefits.
In this series, a large number of patients did not receive antiplatelet therapy. The significant beneficial effect of postoperative aspirin therapy on total mortality, the prevention of recurrent ischemic events and reintervention, emphasizes the importance of this therapy. These data suggest that the previously documented effects of aspirin on 1-year graft patency14 15 correlate with enhanced long-term survival. Some of the patients not receiving aspirin had undergone CABG before the general use of postoperative aspirin at this institution in the early 1980s, while others were no longer patients of this institution and/or had let their aspirin therapy lapse.
In this group of patients, as in other studies,6 7 8 9 10 high incidences of preoperative cigarette smoking and a family history of premature coronary heart disease have been documented. In this cohort, unfortunately, 28% of patients smoked regularly at some time after surgery. Since smoking has been reported to cause late saphenous vein graft thrombosis,4 difficulties in documenting this habit may have contributed to its showing only a trend toward being a significant adverse factor (P=.12). Hypertension was not associated with an adverse outcome (P=.95). Although there was a much smaller percentage of diabetics (5%) in this series than in the Johns Hopkins series19 (17%), this factor was associated with increased late mortality (P=.04). However, because diabetes and smoking are potentially modifiable risk factors, they should receive vigorous attention.
Our study does not address whether CABG is a better treatment than medical therapy. A trial randomizing patients without severely limiting angina or life-threatening coronary anatomy to aggressive lipid-modifying therapy either alone or in conjunction with CABG may be appropriate but, given that young patients are likely to be more insistent in requesting revascularization for symptoms, seems improbable.
Conclusions
To achieve a better long-term outcome in patients
who have
CABG at <40 years old, lipid-modifying therapy, regular
postoperative aspirin, optimal treatment of diabetes, the use of IMA
conduits, and the preservation of left ventricular function
will need to be assiduously addressed.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This work was supported in part by the Green Lane Hospital Research and Educational Fund, Auckland, New Zealand. Dr Harvey White's helpful advice is gratefully acknowledged.
|
Footnotes |
|---|
Reprint requests to Dr John French, Cardiology Department, Green Lane Hospital, Epsom, Auckland 1003, New Zealand.
|
References |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, Morris C, Mathur V, Varnauskas E, Chalmers TC. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344:563-570. [Medline] [Order article via Infotrieve]
2. Varnauskas E, and the European Coronary Surgery Study Group. Twelve-year follow up of survival in the randomized European Coronary Surgery Study. N Engl J Med. 1988;319:332-337. [Abstract]
3.
Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME,
Azen SP, Cashim-Hemphill L. Beneficial effects of combined
colestipol-niacin therapy on coronary
atherosclerosis and coronary venous bypass
grafts. JAMA. 1987;257:3233-3240.
4. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation. 1988;78(suppl I):I-140-I-143.
5. Campeau L, Enjalbert M, Lespérance J, Bourassa MG, Kwiterovich PJ, Wacholder S, Sniderman A. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med. 1984;311:1329-1332. [Abstract]
6. Lytle BW, Kramer JR, Golding LR, Cosgrove DM, Borsh JA, Goormastic M, Loop FD. Young adults with coronary atherosclerosis: 10 year results of surgical myocardial revascularization. J Am Coll Cardiol. 1984;4:445-453. [Abstract]
7.
Kelly ME, DeLaria GA, Hajafi H.
Coronary artery bypass surgery in patients less than 40
years of age. Chest. 1988;94:1138-1141.
8.
Cohen DJ, Basamania C, Graeber GM, Deshong JL, Burge
JR. Coronary artery bypass grafting in young patients
under 36 years of age. Chest. 1986;89:811-816.
9. Laks H, Kaiser GC, Barner HB, Codd JE, Willman VI. Coronary revascularization under age 40 years: risk factors and results of surgery. Am J Cardiol. 1978;41:584-589. [Medline] [Order article via Infotrieve]
10. Kelly TF, Craver JM, Jones EL, Hatcher CR. Coronary revascularization in patients 40 years and younger: surgical experience and long term follow up. Am Surg. 1978;44:675-687. [Medline] [Order article via Infotrieve]
11. Simons LA, Simons J. Coronary risk factors six to 12 months after coronary artery bypass graft surgery. Med J Aust. 1987;146:573-580. [Medline] [Order article via Infotrieve]
12.
Cohen MV, Byrne M-J, Levine B, Gutowski T, Adelson R.
Low rate of treatment of
hypercholesterolemia by cardiologists in
patients with suspected and proven coronary artery
disease. Circulation. 1991;83:1294-1304.
13. Agnew TM, French JK, Neutze JM, Whitlock RML, Brandt PWT, Kerr AR, Webber BJ, Rutherford JD. The role of dipyridamole in addition to aspirin in the prevention of occlusion of coronary artery bypass grafts. Aust N Z J Med. 1992;22:665-670. [Medline] [Order article via Infotrieve]
14. Henderson WG, Goldman S, Copeland JG, Moritz TE, Hasker LA. Antiplatelet or anticoagulant therapy after coronary artery bypass surgery: a meta analysis of clinical trials. Ann Intern Med. 1989;111:743-750.
15.
Antiplatelet Trialists' Collaboration.
Collaborative overview of randomised trials of
antiplatelet therapy, II: maintenance of vascular graft
or arterial patency by antiplatelet
therapy. Br Med J. 1994;308:159-168.
16. Rutherford JD, Whitlock RML, McDonald BW, Barratt-Boyes BG, Kerr AR. Multivariate analysis of the long term results of coronary artery bypass grafting performed during 1976 and 1977. Am J Cardiol. 1986;57:1264-1267. [Medline] [Order article via Infotrieve]
17. Brandt PWT, Partridge JB, Wattie WJ. Coronary arteriography: method of preservation of the arteriogram report and a scoring system. Clin Radiol. 1977;28:361-365. [Medline] [Order article via Infotrieve]
18.
Merry AF, Ramage MC, Whitlock RML, Laycock GJA, Smith
W, Stenhouse D, Wild CJ. First time coronary artery
bypass grafting: the anaesthetist as a risk factor. Br J
Anaesth. 1992;68:6-12.
19. Zehr KJ, Lee PC, Poston RS, Gillinov M, Greene PS, Cameron DE. Two decades of coronary artery bypass graft surgery in young adults. Circulation. 1994;90(part 2):II-133-II-139.
20. Buffet P, Colasante B, Bischoff N, Juillière Y, Danchin N, Feldmann L, Selton-Suty C, Amrein D, Mathieu P, Cherrier F. Fifteen-year follow-up study of coronary surgery with left internal mammary artery bypass grafting to the left anterior descending artery in patients younger than 40 years. Eur Heart J. 1993;14(suppl):171.
21. Ruygrok PN, Agnew TM, Coverdale HA, Kerr AR, Graham KJ, Whitlock RML. Coronary artery surgery in the elderly: long-term follow-up. Aust N Z J Med. 1993;23:489-493. [Medline] [Order article via Infotrieve]
22. Rahimtoola SH, Fessler CL, Grunkemeier GL, Starr A. Survival 15 to 20 years after coronary bypass surgery for angina. J Am Coll Cardiol. 1993;21:151-157. [Abstract]
23.
White HD, Norris RM, Brown MA, Brandt PWT, Whitlock
RML. Left ventricular end-systolic
volume as the major determinant of survival after recovery from
myocardial infarction. Circulation. 1987;76:44-51.
24.
Hamer AW, Takayama M, Abraham KA, Roche AHG, Kerr AR,
Williams BF, Ramage MC, White HD. End-systolic
volume and long-term survival after coronary artery bypass
graft surgery in patients with impaired left ventricular
function. Circulation. 1994;90:2899-2904.
25. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298. [Abstract]
26. French JK, White HD, Greaves SC. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. N Z Med J. 1990;103:41-43. [Medline] [Order article via Infotrieve]
27. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.[Medline] [Order article via Infotrieve]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||